Morphologic and cytogenetic variables affect the flow cytometric recovery of plasma cell myeloma cells in bone marrow aspirates

被引:9
作者
Cogbill, C. H. [1 ]
Spears, M. D. [1 ]
Vantuinen, P. [1 ]
Harrington, A. M. [1 ]
Olteanu, H. [1 ]
Kroft, S. H. [1 ]
机构
[1] Med Coll Wisconsin, Dept Pathol, Milwaukee, WI 53226 USA
关键词
Plasma cells; flow cytometry; myeloma; cytogenetics; plasma cell leukemia; MINIMAL RESIDUAL DISEASE; MULTIPLE-MYELOMA; PLASMABLASTIC MORPHOLOGY; PROGNOSTIC-FACTOR; DIAGNOSIS; TRANSPLANTATION; DISORDERS; LYMPHOMAS; HISTOLOGY; SURVIVAL;
D O I
10.1111/ijlh.12411
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: It is widely recognized that plasma cells (PCs) are under-represented in flow cytometry (FC) studies, but the causes of this phenomenon are poorly understood. We sought to study potential variables that affect PC recovery by flow cytometry (FC) in the analysis of plasma cell myeloma (PCM). Methods: We retrospectively performed PC differential counts and morphologic assessment on PCM peripheral blood (PB) smears, bone marrow (BM) aspirate smears and posterythrocyte lysis cytospins. PCs were enumerated by FC, excluding erythroid events/debris, and were defined as CD38(bright+), CD45(dim to negative) events. PC recovery was calculated as follows: cytospin/aspirate, FC/aspirate, and FC/cytospin. Results: Sixty-four BM analyses from 42 patients showed a mean aspirate PC% of 32.9 +/- 23.2%. The mean PC% decreased in both the cytospin (10.9%) and by FC (8.2%). The difference between PC% in the cytospin and by FC was statistically significant (P < 0.03). Mature PC morphology and lower aspirate PC% had poorer recovery (P < 0.05) but higher-risk cytogenetics (deletions of 13q and TP53) was associated with increased PC recovery. Immunophenotype, heavy chain type, and treatment did not affect PC recovery. PB specimens had superior recovery compared with BM samples. Conclusions: Similar to prior reports, the greatest loss of PC in BM evaluation occurs between the aspirate and postlysis specimens; however, a small amount occurs from further processing. Additional morphologic and cytogenetic factors also appear to influence recovery in addition to overall PC%.
引用
收藏
页码:797 / 808
页数:12
相关论文
共 35 条
  • [1] [Anonymous], 2008, WHO Classification of Tumours of Haematopoietic and Lymphoid tissues, V4th, P200
  • [2] DIAGNOSIS OF MULTIPLE-MYELOMA
    BARTL, R
    FATEHMOGHADAM, A
    [J]. ONKOLOGIE, 1986, 9 (04): : 183 - 195
  • [3] BONE-MARROW HISTOLOGY IN MYELOMA - ITS IMPORTANCE IN DIAGNOSIS, PROGNOSIS, CLASSIFICATION AND STAGING
    BARTL, R
    FRISCH, B
    BURKHARDT, R
    FATEHMOGHADAM, A
    MAHL, G
    GIERSTER, P
    SUND, M
    KETTNER, G
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1982, 51 (03) : 361 - 375
  • [4] Impact of flow cytometry on the diagnosis and characterization of lymphomas, chronic lymphoproliferative disorders and plasma cell neoplasias
    Braylan, RC
    [J]. CYTOMETRY PART A, 2004, 58A (01): : 57 - 61
  • [5] Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3
    Dimopoulos, Meletios
    Kyle, Robert
    Fermand, Jean-Paul
    Rajkumar, S. Vincent
    San Miguel, Jesus
    Chanan-Khan, Asher
    Ludwig, Heinz
    Joshua, Douglas
    Mehta, Jayesh
    Gertz, Morie
    Avet-Loiseau, Herve
    Beksac, Meral
    Anderson, Kenneth C.
    Moreau, Philippe
    Singhal, Seema
    Goldschmidt, Hartmut
    Boccadoro, Mario
    Kumar, Shaji
    Giralt, Sergio
    Munshi, Nikhil C.
    Jagannath, Sundar
    [J]. BLOOD, 2011, 117 (18) : 4701 - 4705
  • [6] Sarasquete ME, 2005, HAEMATOLOGICA, V90, P1365
  • [7] Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients
    Fonseca, R
    Blood, EA
    Oken, MM
    Kyle, RA
    Dewald, GW
    Bailey, RJ
    Van Wier, SA
    Henderson, KJ
    Hoyer, JD
    Harrington, D
    Kay, NE
    Van Ness, B
    Greipp, PR
    [J]. BLOOD, 2002, 99 (10) : 3735 - 3741
  • [8] Mature plasma cells as indicator of better prognosis in multiple myeloma. New methodology for the assessment of plasma cell morphology
    Goasguen, JE
    Zandecki, M
    Mathiot, C
    Scheiff, JM
    Bizet, M
    Ly-Sunnaram, B
    Grosbois, B
    Monconduit, M
    Michaux, JL
    Facon, T
    [J]. LEUKEMIA RESEARCH, 1999, 23 (12) : 1133 - 1140
  • [9] Plasmablastic morphology - An independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group
    Greipp, PR
    Leong, T
    Bennett, JM
    Gaillard, JP
    Klein, B
    Stewart, JA
    Oken, MM
    Kay, NE
    Van Ness, B
    Kyle, RA
    [J]. BLOOD, 1998, 91 (07) : 2501 - 2507
  • [10] GREIPP PR, 1985, BLOOD, V65, P305